Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: A pooled analysis of STARTVerso1 and 2

被引：0

作者：

Yoshida, Eric M. ^{[1
]}

Asselah, Tarik ^{[2
,3
]}

Moreno, Christophe ^{[4
]}

Maevskaya, Marina V. ^{[5
]}

Kao, Jia-Horng ^{[6
]}

Crespo, Javier ^{[7
]}

Dufour, Jean-Francois ^{[8
]}

Wong, David K. ^{[9
]}

Tam, Edward ^{[10
]}

Feinman, Victor S. ^{[11
]}

Schuchmann, Marcus ^{[12
]}

Omata, Masao ^{[13
,14
]}

Ferenci, Peter ^{[15
]}

Kowdley, Kris V. ^{[16
]}

Lee, Youn-Jae ^{[17
]}

Tomita, Eiichi ^{[18
]}

Paik, Seung Woon ^{[19
]}

Yatsuhashi, Hiroshi ^{[20
]}

Stern, Jerry O. ^{[21
]}

Quinson, Anne-Marie ^{[21
]}

Voss, Florian ^{[22
]}

Scherer, Joe ^{[21
]}

Datsenko, Yakov ^{[22
]}

Jensen, Donald M. ^{[23
]}

机构：

[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[2] Univ Paris Diderot, Hop Beaujon, AP HP, Clichy, France

[3] INSERM CRB3, Clichy, France

[4] Univ Libre Brussels, Hop Univ Erasme, Brussels, Belgium

[5] First Moscow State Med Univ, Moscow, Russia

[6] Natl Taiwan Univ Hosp, Taipei, Taiwan

[7] Hosp Univ Valdecilla, Santander, Spain

[8] Univ Clin Visceral Surg & Med, Bern, Switzerland

[9] Toronto Western Hosp Liver Ctr, Toronto, ON, Canada

[10] LAIR Ctr, Vancouver, BC, Canada

[11] Univ Toronto, Mt Sinai Hosp, Hepatitis Ctr, Toronto, ON M5G 1X5, Canada

[12] Univ Hosp Mainz, Mainz, Germany

[13] Yamanishi Cent Hosp, Yamaguchi, Japan

[14] Kita Hosp, Yamaguchi, Japan

[15] Med Univ Vienna, Vienna, Austria

[16] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[17] Inje Univ, Busan Paik Hosp, Pusan, South Korea

[18] Gifu Municipal Hosp, Gifu, Japan

[19] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea

[20] Nagasaki Med Ctr, Nagasaki, Japan

[21] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

[22] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[23] Univ Chicago Med, Chicago, IL USA

来源：

HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1114

引用

页码：751A / 752A

页数：2

共 50 条

[1] STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection
Ferenci, Peter
Asselah, Tarik
Foster, Graham R.
Zeuzem, Stefan
Sarrazin, Christoph
Moreno, Christophe
Ouzan, Denis
Maevskaya, Marina
Calinas, Filipe
Morano, Luis E.
Crespo, Javier
Dufour, Jean-Francois
Bourliere, Marc
Agarwal, Kosh
Forton, Daniel
Schuchmann, Marcus
Zehnter, Elmar
Nishiguchi, Shuhei
Omata, Masao
Kukolj, George
Datsenko, Yakov
Garcia, Miguel
Scherer, Joseph
Quinson, Anne-Marie
Stern, Jerry O.
JOURNAL OF HEPATOLOGY, 2015, 62 (06) : 1246 - 1255
[2] Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotype-1 Infection: A Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2)
Jensen, Donald M.
Foster, Graham
Ferenci, Peter
Cooper, Curtis
Dieterich, Douglas T.
Sulkowski, Mark
Mantry, Parvez S.
Buynak, Robert
Hassanein, Tarek
Lee, William M.
Wright, David
Tam, Edward
Kaita, Kelly
Feinman, S. Victor
Scherer, Joseph
Olson, Stephen
Quinson, Anne-Marie
GASTROENTEROLOGY, 2014, 146 (05) : S974 - S974
[3] A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection
Jensen, Donald M.
Asselah, Tarik
Dieterich, Douglas T.
Foster, Graham R.
Sulkowski, Mark S.
Zeuzem, Stefan
Mantry, Parvez S.
Moreno, Christophe
Ouzan, Denis
Wright, Mark
Morano, Luis
Buynak, Robert
Bourliere, Marc
Hassanein, Tarek
Nishiguchi, Shuhei
Kao, Jia-Horng
Omata, Masao
Paik, Seung Woon
Wong, David K.
Tam, Edward
Kaita, Kelly D.
Feinman, Victor S.
Stern, Jerry O.
Garcia, Miguel
Quinson, Anne-Marie
Voss, Florian
Gallivan, John-Paul
Boecher, Wulf O.
Ferenci, Peter
HEPATOLOGY, 2013, 58 : 734A - 735A
[4] Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection
Nishiguchi, Shuhei
Sakai, Yoshiyuki
Kuboki, Makoto
Tsunematsu, Satoshi
Urano, Yasuhisa
Sakamoto, Wataru
Tsuda, Yasuhiro
Steinmann, Gerhard
Omata, Masao
LIVER INTERNATIONAL, 2014, 34 (01) : 78 - 88
[5] Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naive Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial
Moreno, Christophe
Ferenci, Peter
Asselah, Tarik
Foster, Graham
Zeuzem, Stefan
Sarrazin, Christoph
Maevskaya, Marina
Calinas, Filipe
Enrique Morano, Luis
Crespo, Javier
Dufour, Jean-Francois
Bourliere, Marc
Agarwal, Kosh
Forton, Daniel
Schuchmann, Marcus
Zehnter, Elmar
Nishigushi, Shuhei
Omata, Masao
Stern, Jerry
Datsenko, Yakov
Scherer, Joseph
Quinson, Anne-Marie
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S145 - S145
[6] FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL
Ferenci, P.
Asselah, T.
Foster, G. R.
Zeuzem, S.
Sarrazin, C.
Moreno, C.
Ouzan, D.
Maevskaya, M.
Calinas, F.
Morano, L. E.
Crespo, J.
Dufour, J. -F.
Bourliere, M.
Agarwal, K.
Forton, D.
Schuchmann, M.
Zehnter, E.
Nishiguchi, S.
Omata, M.
Stern, J. O.
Datzenko, Y.
Scherer, J.
Quinson, A. -M.
JOURNAL OF HEPATOLOGY, 2013, 58 : S569 - S570
[7] Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial
Ferenci, P.
Asselah, T.
Foster, G. R.
Zeuzem, S.
Sarrazin, C.
Moreno, C.
Ouzan, D.
Maevskaya, M.
Calinas, F.
Morano, L. E.
Crespo, J.
Dufour, J-F
Bourliere, M.
Agarwal, K.
Forton, D.
Schuchmann, M.
Zehnter, E.
Nishiguchi, S.
Omata, M.
Stern, J.
Datzenko, Y.
Scherer, J.
Quinson, A. M.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 157 - 158
[8] VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION
Asselah, T.
Jensen, D. M.
Foster, G. R.
Sulkowski, M. S.
Ouzan, D.
Morano, L.
Buynak, R.
Agarwal, K.
Hassanein, T.
Forton, D.
Cho, M.
Genne, D.
Kaita, K.
Maieron, A.
Preotescu, L.
Sarrazin, C.
Zehnter, E.
Streinu-Cercel, A.
Stern, J. O.
Datsenko, Y.
Drulak, M.
Voss, F.
Quinson, A. -M.
Ferenci, P.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S311 - S311
[9] Virological Response in Treatment-Naive Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction
Asselah, Tarik
Jensen, Donald M.
Foster, Graham
Sulkowski, Mark
Ouzan, Denis
Morano, Luis
Buynak, Robert
Agarwal, Kosh
Hassanein, Tarek
Forton, Daniel
Cho, Mong
Genne, Daniel
Kaita, Kelly
Maieron, Andreas
Preotescu, Liliana
Sarrazin, Christoph
Zehnter, Elmar
Streinu-Cercel, Adrian
Stern, Jerry O.
Datsenko, Yakov
Drulak, Murray
Voss, Florian
Quinson, Anne-Marie
Ferenci, Peter
GASTROENTEROLOGY, 2014, 146 (05) : S975 - S976
[10] Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype1 HCV: SILEN-C1 trial
Sulkowski, Mark S.
Asselah, Tarik
Lalezari, Jacob
Ferenci, Peter
Fainboim, Hugo
Leggett, Barbara
Bessone, Fernando
Mauss, Stefan
Heo, Jeong
Datsenko, Yakov
Stern, Jerry O.
Kukolj, George
Scherer, Joseph
Nehmiz, Gerhard
Steinmann, Gerhard G.
Boecher, Wulf O.
HEPATOLOGY, 2013, 57 (06) : 2143 - 2154

← 1 2 3 4 5 →